Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial | MicrobiomeTrials
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-01Est. Completion: 2027-01-01
Enrollment target: 33 participants
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States